| 000 | 04339nam a22003735i 4500 | ||
|---|---|---|---|
| 001 | 106827 | ||
| 003 | ESmaUEC | ||
| 005 | 20230102113315.0 | ||
| 006 | a||||fo|||| 00| 0 | ||
| 007 | cr nn nnnaamaa | ||
| 008 | 181108s2018 gw | s |||| 0|eng d | ||
| 020 |
_a9783319977461 _9 |
||
| 024 | 7 |
_a10.1007/978-3-319-97746-1 _2doi |
|
| 040 |
_aES-MaUEC _bspa _cES-MaUEC |
||
| 050 | 4 |
_aRC268.4 _b2018 EB |
|
| 245 | 0 | 0 |
_aBiological Mechanisms of Minimal Residual Disease and Systemic Cancer _cedited by Julio A. Aguirre-Ghiso |
| 264 | 1 |
_aCham _bSpringer International Publishing _c2018 |
|
| 300 |
_a1 recurso en línea (IX, 162 páginas) _b13 ilustraciones, 10 ilustraciones a color |
||
| 336 |
_aTexto _btxt _2rdacontent |
||
| 347 |
_atext file _bPDF _2rda |
||
| 490 | 0 |
_aAdvances in Experimental Medicine and Biology _x0065-2598 _v1100 |
|
| 505 | 0 | _aPreface -- Foreword. Understanding and targeting minimal residual disease: a path to change cancer patient outcomes -- Epigenetics and Pluripotency Aspects of Disseminated Cancer Cells during Minimal Residual Disease -- Anti-angiogenic therapy-mediated endothelial damage: A driver of breast cancer recurrence?- Minimal Residual Disease in Prostate Cancer -- Minimal Residual Disease in Head and Neck Cancer and Esophageal Cancer -- Detection of Minimal Residual Disease and its Clinical Applications in Melanoma and Breast Cancer Patients Selena -- Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.-Minimal Residual Disease in Acute Myeloid leukemia -- Characteristics and therapeutic targeting of minimal residual disease in childhood acute lymphoblastic leukemia -- Minimal Residual Disease in Multiple Myeloma: Impact on response assessment, prognosis and tumor heterogeneity -- Index. . | |
| 520 | 3 | _aThis book focuses on the biological mechanisms of minimal residual disease (MRD) and recurrence. It integrates this biology in solid cancers and in hematological malignancies. It reports also on technological advancements for monitoring MRD, derived from mechanistic insights. Chapters in solid and hematological malignancies address stem cell biology, genetics, epigenetics and micro-environmental regulation of dormant MRD. Novel insight into technologies for molecular phenotyping of MRD and monitoring of CTCs, DTCs and cell free RNA and DNA are also addressed extensively. Five chapters explore the above concepts in solid cancers such as prostate, breast, melanoma, head and neck and esophageal. Two chapters also explore the basic mechanisms of vascular biology targeting and epigenetic mechanisms regulating pluripotency programs during dormancy. Similar biology is explored in hematological malignancies such as T-ALL, CML, AML and multiple myeloma in additional four chapters. This book is edited and prefaced by Dr. Julio Aguirre-Ghiso, an expert in dormancy and recurrence. The chapters are written by world-recognized experts Drs. Ravi Bahtia, Samir Parekh, Russel Taichman, Monica Guzman, David Hoon, Denis Schewe, Irmela Jeremias, Cyrus Ghajar, Maria Soledad Sosa and Nicholas Stoecklein. The topic of this book is of particular interest to both basic cancer cell biologists and physician scientists that are working to provide a more integrated view of the biology of MRD and to those interested in working on or learning about this paradigm. The integrated and cross-disciplinary focus of the book from biology to medicine seeks to help bridge gaps to improve cancer care and prevent recurrences. | |
| 650 | 7 |
_aCáncer _xAspectos genéticos _9273952 _2embne |
|
| 700 | 1 |
_aAguirre-Ghiso, Julio A _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _1http://viaf.org/viaf/140154981891267742659 |
|
| 710 | 2 |
_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996 |
|
| 776 | 0 | 8 |
_iPrinted edition: _z9783319977454 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783319977478 |
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-97746-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 490 | 0 | _aBiomedical and Life Sciences (Springer-11642) | |
| 942 | _2lcc | ||
| 988 | _aEBSPRINGER_BIOMEDLIFE_2019 | ||
| 998 |
_aSI _a_alco _a_vill _b01/2019 _cm _dz _ef _feng _ggw _h0 |
||
| 999 |
_c106827 _d106827 _x1 |
||